Insulet Brings in 2 Big Partnerships with CGM Powerhouses Abbott and DexCom

Insulet has snared two partnerships that will help it continue its strong momentum in the continuous glucose monitoring (CGM) market. The Billerica, MA-based company and one of the 25 most attractive medtech firms on the M&A radar, announced it had signed agreements with both Abbott Laboratories and DexCom. The agreements center around Insulet’s Omnipod Horizon Automated Insulin Delivery (AID) System, which is in pivotal trials in the U.S. The Omnipod Horizon System will be integrated with Abbott’s Freestyle Libre 2, which has approval in Europe. The Freestyle Libre 2 has not yet received a nod from FDA and is one of the most anticipated technologies to hit the U.S. market. The companies said this integrated system will be designed to always remain in automated insulin delivery mode and can be controlled through an app on a user's personal smartphone to manually take a dose of fast-acting insulin, or bolus, before meals for optimal performance. Additionally, the integrated platform is expected to be the first combined system with a fully disposable wearable sensor and pump. “As diabetes care becomes more interoperable, we're developing more connected approaches to improve care,” Jared Watkin, senior vice president, Diabetes Care, Abbott, said in a release.“Through this partnership, Abbott and Insulet will offer an integrated digital health platform that is simple and accurate and wil...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Business Source Type: news